GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Third Harmonic Bio
Third Harmonic is a biotech company developing drugs to treat inflammatory diseases. Its stock price is highly volatile and dependent on clinical trial results, which is typical for early-stage biotechs.
Share prices of companies in the market segment - Pharma immune
Third Harmonic Bio is a biopharmaceutical company developing oral medications for the treatment of inflammatory and allergic diseases. We have classified it in the Pharma: Immunology group. The chart below shows how investors are evaluating new approaches to treating chronic inflammation.
Broad Market Index - GURU.Markets
Third Harmonic Bio is a biotech company developing drugs to treat inflammatory diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Third Harmonic shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
THRD - Daily change in the company's share price Third Harmonic Bio
For Third Harmonic Bio, Inc., an immunology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Pharma immune
Third Harmonic Bio is a biopharmaceutical company specializing in developing drugs to treat inflammatory diseases. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this area, allowing you to assess the performance of THRD stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Third Harmonic is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Third Harmonic Bio
For Third Harmonic Bio, the year-over-year trend is a story about the development of its drug for the treatment of inflammatory skin diseases. Its 12-month market cap is entirely dependent on clinical trial data. The success of its highly selective KIT inhibitor could offer a new approach to treating urticaria and other severe conditions.
Annual dynamics of market capitalization of the market segment - Pharma immune
As an early-stage biotech company, Third Harmonic is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its drugs. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Third Harmonic Bio is a biotech company whose value is locked into its pipeline of drugs. Its shares move with clinical trial news, not economic cycles. A sharp rise or fall amid a calm market is clear evidence that investors are betting on science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Third Harmonic Bio
Third Harmonic is a clinical-stage biopharmaceutical company. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its skin treatment drug is a key event for investors.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Third Harmonic Bio is a clinical-stage biotech company developing an oral drug for the treatment of inflammatory diseases such as chronic urticaria. The chart below illustrates the overall dynamics of the biotech sector, where the search for effective treatments for immune diseases is a priority.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Third Harmonic Bio is a clinical-stage biotech company developing drugs to treat allergic and inflammatory diseases. Its shares are preoccupied with anticipation of research results, and their performance is completely unrelated to general market cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Third Harmonic Bio
Shares of Third Harmonic, a biotech company, reflect the search for drugs for inflammatory diseases every week. The stock price is reacting to clinical trial data for its targeted drug, which may offer a new approach to treating hives and asthma.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Third Harmonic Bio develops oral medications for the treatment of allergic and inflammatory diseases. The chart will help separate its own news-driven dynamics from the overall volatility of the pharmaceutical sector, revealing how the market views its chances of success in this competitive field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Third Harmonic Bio is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether Third Harmonic is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
THRD - Market capitalization of the company Third Harmonic Bio
Third Harmonic's market capitalization chart tells the story of a biotech company focused on treating allergic and inflammatory diseases. Its decline reflects the failure of its lead drug in clinical trials due to safety concerns. Its dynamics reflect the market's assessment of its chances of recovery.
THRD - Share of the company's market capitalization Third Harmonic Bio within the market segment - Pharma immune
Third Harmonic Bio is a biotech company focused on treating allergic and inflammatory diseases. Its market capitalization reflects the potential of its lead drug. The chart below shows how its market capitalization changes based on clinical trial data.
Market capitalization of the market segment - Pharma immune
Third Harmonic Bio is a clinical-stage biotech company focused on treating inflammatory diseases. The chart below shows the overall market capitalization of this sector. Its volatile dynamics reflect the hopes and risks that accompany the long journey of drug discovery.
Market capitalization of all companies included in a broad market index - GURU.Markets
Third Harmonic Bio is a biotech company working in the field of immunology. The market capitalization of clinical-stage companies reflects investors' faith in the scientific hypothesis and the team. Their volatility on the overall chart reflects the long and risky path from idea to potential cure.
Book value capitalization of the company, segment and market as a whole
THRD - Book value capitalization of the company Third Harmonic Bio
Third Harmonic Bio's balance sheet represents its capital invested in the development of oral medications for the treatment of allergic and inflammatory diseases. This provides a tangible, scientific foundation for the search for therapies for urticaria and asthma. How has this biotech asset changed during clinical trials? The chart below shows its dynamics.
THRD - Share of the company's book capitalization Third Harmonic Bio within the market segment - Pharma immune
Third Harmonic Bio develops drugs to treat inflammatory diseases, which requires R&D laboratories. The chart shows the share of these science-intensive tangible assets, reflecting the physical foundation of its scientific activities.
Market segment balance sheet capitalization - Pharma immune
Third Harmonic, a development-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Third Harmonic's balance sheet is its intellectual property, a KIT inhibitor drug designed to treat severe forms of urticaria and other allergic diseases. The company's assets are capitalized science. The chart below shows how this highly specialized biotech stacks up in terms of assets.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Third Harmonic Bio
Third Harmonic Bio is a biotech company focused on treating allergic and inflammatory diseases. Its balance sheet represents R&D expenses. Its market capitalization represents investors' hope that its specific treatment approach will be successful. The chart reflects faith in its scientific hypothesis.
Market to book capitalization ratio in a market segment - Pharma immune
Third Harmonic Bio is a biotech company developing drugs to treat severe inflammatory diseases. Its market valuation on the chart is speculative and depends entirely on the success of its lead drug candidate's clinical trials, reflecting investor expectations.
Market to book capitalization ratio for the market as a whole
Third Harmonic Bio is a biotech company whose value depends almost entirely on the success of its lead drug candidate's clinical trials. This chart clearly demonstrates how high the premium for a potential medical breakthrough can be compared to the average market valuation.
Debts of the company, segment and market as a whole
THRD - Company debts Third Harmonic Bio
Third Harmonic Bio, a clinical-stage biotech developing drugs to treat inflammatory diseases, uses capital to fund its research. This chart shows how the company raises funds to test its scientific hypothesis and advance its lead candidate through the costly trial process.
Market segment debts - Pharma immune
Third Harmonic Bio is a clinical-stage biotech developing drugs to treat inflammatory diseases. This chart shows that the company, like its peers, funds its expensive research exclusively with equity, avoiding the burden of debt until potential success.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Third Harmonic Bio
Third Harmonic Bio is a biotech company focused on treating inflammatory diseases. Its operations require significant investment in clinical research. This chart shows the extent to which the company relies on debt to finance its development, which is a measure of its financial risk on the path to commercialization.
Market segment debt to market segment book capitalization - Pharma immune
Third Harmonic Bio is a biotech company developing drugs to treat allergic and inflammatory diseases. Its lead candidate failed in clinical trials. This chart shows debt trends in the biotech sector, helping to assess the financial difficulties companies face after R&D failures.
Debt to book value of all companies in the market
Third Harmonic Bio, a clinical-stage biopharmaceutical company focused on treating inflammatory diseases, requires significant capital. This chart, reflecting the overall market leverage, provides context. It helps us understand how its financial strategy is typical for biotech, where revenue is deferred for years and expenses are high.
P/E of the company, segment and market as a whole
P/E - Third Harmonic Bio
Third Harmonic Bio is a clinical-stage biopharmaceutical company developing oral drugs for the treatment of inflammatory diseases. This chart shows how investors view its targeted approach. This assessment depends on clinical trial results and the potential to offer a convenient treatment for patients.
P/E of the market segment - Pharma immune
This industry metric represents the average P/E for biotech companies. For Third Harmonic Bio, which treats inflammatory diseases, it serves as a benchmark. It reflects the overall level of investor confidence in the sector, providing context for valuing a company that relies on its unique scientific approach.
P/E of the market as a whole
Third Harmonic Bio is a biopharmaceutical company specializing in the development of drugs for the treatment of inflammatory diseases. Its valuation is entirely dependent on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Third Harmonic Bio
This chart for Third Harmonic Bio, Inc., a biopharmaceutical company developing drugs to treat inflammatory diseases, shows market expectations for its clinical pipeline. It reflects investor confidence in the potential of its lead candidate for the treatment of urticaria and asthma.
%20P%2FE%20Third%20Harmonic%20Bio&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Third-Harmonic-Bio&v=1772513602307 "Chart of the company's future (projected) P/E Third Harmonic Bio")
Future (projected) P/E of the market segment - Pharma immune
Third Harmonic Bio is a clinical-stage biopharmaceutical company developing an oral KIT inhibitor for the treatment of inflammatory diseases, particularly chronic urticaria. The chart shows industry forecasts, allowing for a comparison of how the market views Third Harmonic's targeted approach to treating allergic and inflammatory conditions.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513602323 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Third Harmonic Bio, Inc. is a biotech company specializing in the treatment of inflammatory diseases. The company's valuation depends on the success of its clinical trials. This graph of overall risk appetite shows how willing investors are to invest in long-term, risky biotech projects targeting large markets.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513602328 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Third Harmonic Bio
Third Harmonic Bio is a clinical-stage biopharmaceutical company developing an oral treatment for inflammatory diseases such as urticaria. Its financial results are based on R&D losses. This chart shows the cost of developing targeted therapies for allergic and inflammatory conditions.
Profit of companies in the market segment - Pharma immune
Third Harmonic Bio is a biopharmaceutical company developing an oral treatment for severe allergic and inflammatory conditions, such as chronic urticaria. This chart, which shows the profitability of the pharmaceutical sector, demonstrates the high demand for treatments for these conditions. Their goal is to offer patients an effective and convenient solution.
Overall market profit
Third Harmonic Bio is a biopharmaceutical company developing targeted therapies for inflammatory diseases. Its lead candidate targets mast cells, key cells in allergic reactions. Success depends on clinical trial results. This total return chart reflects the investment climate, which is important for funding such innovative approaches.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Third Harmonic Bio
Third Harmonic Bio is a biotech company developing an oral KIT inhibitor for the treatment of severe allergic and inflammatory diseases, such as chronic urticaria. This chart summarizes analyst opinions on the clinical prospects and commercial potential of their drug in a market with high unmet needs.
%20profit%20of%20the%20company%20Third%20Harmonic%20Bio&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Third-Harmonic-Bio&v=1772513602387 "Graph of future (projected) profit of the company Third Harmonic Bio")
Future (predicted) profit of companies in the market segment - Pharma immune
Third Harmonic Bio is a clinical-stage biopharmaceutical company developing drugs to treat inflammatory diseases such as urticaria. Its future depends on the success of clinical trials. This biotech chart reflects overall investor sentiment and their expectations for companies developing new classes of drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513602412 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Third Harmonic Bio is a biotech company focused on treating inflammatory diseases. Its value is determined by the potential of its scientific developments. The overall economic sentiment reflected by this forecast influences the valuation of the entire biotech industry and investors' risk appetite.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513602423 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Third Harmonic Bio
Third Harmonic Bio is a biopharmaceutical company developing drugs to treat allergic and inflammatory diseases. For a clinical-stage company, this chart is key. It shows how investors view its scientific approach and potential future sales, placing bets on success in treating common diseases.
P/S market segment - Pharma immune
Third Harmonic Bio is a biopharmaceutical company developing oral therapies for the treatment of inflammatory diseases. The clinical-stage company's valuation is based on the future potential of its lead candidate. This chart, which displays average biotech valuations, helps understand how the market views Third Harmonic's scientific approach and prospects.
P/S of the market as a whole
Third Harmonic Bio is a biopharmaceutical company developing an oral treatment for severe urticaria and other inflammatory diseases caused by mast cells. This chart, which reflects market revenue estimates, is a measure of Third Harmonic's hopes. It shows how much investors value the potential of developing a convenient treatment.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Third Harmonic Bio
Third Harmonic Bio is a clinical-stage biotech company focused on developing oral therapies for mastocytosis and other inflammatory diseases. This chart reflects investor expectations that its lead candidate will successfully complete clinical trials and become an effective and convenient treatment.
%20P%2FS%20Third%20Harmonic%20Bio&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Third-Harmonic-Bio&v=1772513602487 "The graph of the company's future (projected) P/S Third Harmonic Bio")
Future (projected) P/S of the market segment - Pharma immune
Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of oral therapies for the treatment of allergic and inflammatory diseases. This chart reflects average revenue expectations in the biotech sector, providing insight into how the market perceives Third Harmonic Bio's potential.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513602498 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Third Harmonic Bio is a biopharmaceutical company developing targeted therapies for inflammatory diseases such as chronic urticaria. This chart reflects the market's overall revenue expectations. The company's success could offer patients new, more effective, and safer treatments for debilitating chronic conditions.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513602517 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Third Harmonic Bio
This chart shows the revenue of Third Harmonic Bio, a clinical-stage biopharmaceutical company focused on treating inflammatory diseases. Its revenue, if any, is generated not from sales but from collaboration fees, reflecting the progress of its oral drug clinical trials.
Sales of companies in the market segment - Pharma immune
Third Harmonic Bio is a biopharmaceutical company developing oral medications for the treatment of inflammatory diseases such as urticaria. This chart illustrates the growth of the immunology market. The company's focus on highly selective KIT kinase inhibitors could lead to the development of first-in-class treatments for a range of allergic and inflammatory conditions.
Overall market sales
Third Harmonic Bio is a biopharmaceutical company focused on treating inflammatory diseases. Its prospects depend on the success of clinical trials. The overall economic situation, shown in this chart, affects the availability of capital for funding long-term biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Third Harmonic Bio
Third Harmonic Bio is a biotech company developing an oral drug for the treatment of severe allergic and inflammatory diseases, such as urticaria. Future revenue is dependent on the success of its lead candidate. The chart below reflects expectations for its commercial potential.
%20sales%20of%20the%20company%20Third%20Harmonic%20Bio&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Third-Harmonic-Bio&v=1772513602570 "Schedule of future (projected) sales of the company Third Harmonic Bio")
Future (projected) sales of companies in the market segment - Pharma immune
Third Harmonic Bio is a biopharmaceutical company specializing in the development of oral inhibitors of KIT, a mutated protein that is responsible for many mastocytosis-mediated inflammatory diseases, such as urticaria. This chart shows the forecast for the overall immunotherapy market, where Third Harmonic Bio is seeking its niche.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513602595 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Third Harmonic Bio is a clinical-stage biotech company specializing in the development of oral KIT inhibitors for the treatment of inflammatory diseases. Its valuation is dependent on the success of clinical trials. This schedule, reflecting investor sentiment, impacts the availability of capital for funding research in highly competitive fields.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513602598 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Third Harmonic Bio
Third Harmonic Bio is a biotech company developing drugs to treat inflammatory diseases such as urticaria. Being in the clinical stage, it incurs significant research expenses. This chart shows its net losses—investments in developing a targeted drug that could offer a new solution for patients with debilitating allergic reactions.
Market segment marginality - Pharma immune
Third Harmonic Bio is a clinical-stage biopharmaceutical company specializing in the development of oral medications for the treatment of inflammatory diseases such as chronic urticaria. Profitability is a long-term goal. This chart reflects clinical trial costs. Investors evaluate it in the context of potential in the large allergy market.
Market marginality as a whole
Third Harmonic Bio is a biotech company focused on developing an oral treatment for severe inflammatory diseases such as chronic urticaria. This overall profitability curve is irrelevant to them. Their future depends solely on the results of their clinical program and the market potential of their drug.
Employees in the company, segment and market as a whole
Number of employees in the company Third Harmonic Bio
Third Harmonic Bio is a clinical-stage biotech company focused on treating inflammatory diseases. It operates with a small team of experts. This chart reflects its lean, R&D-focused model, with many functions outsourced.
Share of the company's employees Third Harmonic Bio within the market segment - Pharma immune
Third Harmonic Bio is a biopharmaceutical company focused on developing an oral drug for the treatment of inflammatory diseases. This chart reflects its share of the total number of researchers in this field. It is an indicator of the scale of its clinical programs and the size of the scientific team working to create a patient-friendly treatment.
Number of employees in the market segment - Pharma immune
Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for inflammatory diseases. This chart shows employment trends in the immunology sector. The growing number of scientists and clinicians here signals progress in clinical research and the company's commitment to creating a convenient tablet alternative to injectables.
Number of employees in the market as a whole
Third Harmonic Bio is a biotech company developing drugs to treat allergic and inflammatory diseases. Its development requires significant investment in R&D. The overall economic stability illustrated by this chart impacts the availability of capital to fund long-term and risky clinical trials.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Third Harmonic Bio (THRD)
Third Harmonic Bio is a biotech company focused on drugs for the treatment of inflammatory diseases (e.g., urticaria). It's an R&D company. The chart shows that the market value is the valuation of their lead drug candidate. The market value per employee (scientist) is high, reflecting the potential of their intellectual property.
%20of%20the%20company%20Third%20Harmonic%20Bio%20(THRD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Third-Harmonic-Bio-THRD&v=1772513602681 "Chart of market capitalization per employee (in thousands of dollars) of the company Third Harmonic Bio (THRD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Third Harmonic Bio is a biopharmaceutical company focused on developing drugs to treat inflammatory diseases. Like many companies in this sector, its value is determined by the potential of its clinical programs. This chart shows the market valuation of its research assets and prospects based on its small team of scientists.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513602714 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Third Harmonic Bio is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory diseases. The chart shows the scientific potential assessment. It reflects the market's perception of their lead drug, where the contribution of a small team of scientists could lead to the creation of a new standard of care.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513602741 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Third Harmonic Bio (THRD)
Third Harmonic Bio is a clinical-stage biotech company specializing in developing drugs to treat allergic and inflammatory diseases. This is R&D. This chart shows the company's capital burn rate: the amount of capital the company spends on each scientist during expensive clinical trials.
%20Chart%20Third%20Harmonic%20Bio%20(THRD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Third-Harmonic-Bio-THRD&v=1772513602747 "Company Profit Per Employee (in thousands of dollars) Chart Third Harmonic Bio (THRD)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Third Harmonic Bio is a clinical-stage biotech company developing drugs for the treatment of allergic and inflammatory diseases. This metric (loss per employee) reflects the high cost of R&D and clinical trials in this competitive field.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513602751 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Third Harmonic Bio (THRD) is a clinical-stage biotech company specializing in immunology. It's an R&D company and has no profit. This chart shows the company's capital burn rate: the operating loss per research team developing a new drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513602767 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Third Harmonic Bio (THRD)
Third Harmonic Bio is a biopharmaceutical company focused on developing drugs for the treatment of inflammatory diseases. This chart reflects the progress of monetizing its research. Revenue growth at this stage will depend on the success of clinical trials and potential partnerships with major pharmaceutical companies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Third-Harmonic-Bio-THRD&v=1772513602789 "Sales chart per company employee Third Harmonic Bio (THRD)")
Sales per employee in the market segment - Pharma immune
Third Harmonic Bio (THRD) is a biotech company focused on developing treatments for inflammatory and allergic diseases (such as chronic urticaria). While in the clinical stage, their revenue (if any) comes from partnerships. This chart shows how productive their R&D team is per scientist.
Sales per employee for the market as a whole
Third Harmonic Bio (THRD) is a clinical-stage biotech company specializing in drugs for the treatment of inflammatory diseases (such as urticaria). The company has no commercial revenue yet. This chart illustrates a typical R&D situation: the entire research team is working on developing future drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Third Harmonic Bio (THRD)
Third Harmonic Bio is a biotech company that suffered a major setback in clinical trials for its lead drug. The bearish sentiment shown by this chart is a bet that the company will be unable to recover from this setback and that its remaining pipeline is worthless.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Third-Harmonic-Bio-THRD&v=1772513602818 "Short Shares Chart for the Company Third Harmonic Bio (THRD)")
Shares shorted by market segment - Pharma immune
Third Harmonic Bio (THRD) is a biotech company developing drugs to treat inflammatory and allergic diseases. This is a competitive but large market. This chart shows the total bearish bets against the entire immunotherapy sector. A rising figure signals that investors are skeptical of the success of new treatment approaches in this segment.
Shares shorted by the overall market
Third Harmonic Bio is a clinical-stage biotech focused on inflammatory diseases. This chart illustrates the overall market pessimism. When fear reigns, investors are reluctant to finance a cash burn. They sell off shares of pre-profitable companies like THRD, preferring to cash out until the market calms down.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Third Harmonic Bio (THRD)
Third Harmonic Bio (THRD) is a biotech company developing drugs to treat inflammatory and allergic diseases (such as hives). This chart measures the rate of price change. It helps identify when investor enthusiasm (above 70) for trial data or disappointment (below 30) peaks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Third-Harmonic-Bio-THRD&v=1772513602860 "RSI 14 indicator chart for the company's stock Third Harmonic Bio (THRD)")
RSI 14 Market Segment - Pharma immune
Third Harmonic is a biotech company focused on *mast cells*. Their signature product is an *oral* KIT inhibitor (bezuclastinib) for the treatment of *allergic* and *inflammatory* diseases (urticaria). The "Pharma-immune" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the *entire* segment. It helps us understand: is THRD's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
Third Harmonic Bio (THRD) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast THRD (Third Harmonic Bio)
Third Harmonic Bio is a biotech company developing oral (tablet-based) drugs for the treatment of inflammatory diseases (such as urticaria). This chart shows the average 12-month forecast of analysts, representing their collective speculative bet on the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-THRD-Third-Harmonic-Bio&v=1772513602897 "A chart showing analyst consensus forecasts for the expected stock price. THRD (Third Harmonic Bio)")
The difference between the consensus estimate and the actual stock price THRD (Third Harmonic Bio)
Third Harmonic (THRD) is a biotech company focused on developing an oral drug for the treatment of chronic urticaria. This chart shows the difference between the market valuation and the consensus estimate. It reflects whether experts believe in their R&D pipeline after previous failures in other programs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-THRD-Third-Harmonic-Bio&v=1772513602911 "A chart showing the difference between the consensus forecast and the actual stock price. THRD (Third Harmonic Bio)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Third Harmonic Bio is a biotech company focused on treating inflammatory diseases (urticaria). Its R&D focus is on a highly selective KIT inhibitor. This chart shows analysts' overall expectations for the immune pharma sector. It reflects whether experts believe breakthroughs in the treatment of chronic inflammation are possible.
Analysts' consensus forecast for the overall market share price
Third Harmonic Bio (THRD) is a clinical-stage biopharmaceutical company focused on treating immunological diseases. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It serves as an indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Third Harmonic Bio
Third Harmonic Bio is a clinical-stage biotech focused on developing KIT inhibitors for the treatment of inflammatory and allergic diseases. Like many biotechs, their value is driven by the potential of a single lead drug. This chart is a comprehensive barometer reflecting market perception of clinical trial data, the safety profile, and the risks inherent to the sector.
AKIMA Market Segment Index - Pharma immune
Third Harmonic Bio (THRD) is a pharma-immuno biotech. They are betting on a single target (a KIT inhibitor), which they hope will be key to treating asthma and allergies. This chart compares their composite index to the immunology sector average.
The AKIM Index for the overall market
Third Harmonic Bio is a biotech company developing KIT inhibitors for the treatment of allergic and inflammatory diseases (urticaria). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this scientific company, with significant financial resources, compares to overall economic trends.
